[131I]Metaiodobenzylguanidine therapy in neural crest tumors: varying outcome in different histopathologies

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Nuclear medicine communications

• Publication date

  2011-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MNM.0b013e32834bad97PMID 21968432
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors.

  2010cited by this paper
• Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.

  2009cited by this paper
• 131I-MIBG Therapy in metastatic phaeochromocytoma and paraganglioma

  2008cited by this paper
• Iodine‐131 metaiodobenzylguanidine treatment for metastatic carcinoid

  2004cited by this paper
• 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients

  1999cited by this paper
• The treatment of malignant pheochromocytoma with Iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients

  1997cited by this paper
• Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.

  1996cited by this paper
• First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma.

  1995cited by this paper
• Critical observations on neuroblastoma treatment with 131-I-metaiodobenzylguanidine at diagnosis.

  1993cited by this paper
• Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

  1993cited by this paper
• Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment.

  1993cited by this paper
• Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation.

  1992cited by this paper
• Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial.

  1991cited by this paper
• Monoclonal antibodies and neuroblastoma.

  1989cited by this paper
• Scintigraphy and treatment of medullary carcinoma of the thyroid with iodine-131 metaiodobenzylguanidine.

  1987cited by this paper
• Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.

  1985cited by this paper
• MALIGNANT PHAEOCHROMOCYTOMA: CLINICAL, BIOCHEMICAL AND SCINTIGRAPHIC CHARACTERIZATION

  1984cited by this paper
• Scintigraphic localization of pheochromocytoma.

  1981cited by this paper

• Metastatic Extra-Adrenal Pheochromocytoma with Single Kidney and Renal Compromise: A Case Report of Excellent Response, Tolerability, and Outcome to a Modified Regimen of 131I-mIBG, and Decision-Making between 131I-mIBG Therapy and PRRT

  2022cites this paper
• Role of imaging test with radionuclides in the diagnosis and treatment of pheochromocytomas and paragangliomas.

  2022cites this paper
• Response to targeted radionuclide therapy with [131I]MIBG AND [177Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: A systematic review

  2022cites this paper
• [177Lu]Lu-DOTA-TATE and [131I]MIBG Phenotypic Imaging-Based Therapy in Metastatic/Inoperable Pheochromocytomas and Paragangliomas: Comparative Results in a Single Center

  2022influential citation
• An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma

  2021cites this paper
• Papel de las pruebas de imagen con radionúclidos en el diagnóstico y tratamiento de los feocromocitomas y paragangliomas

  2021cites this paper
• 131I-MIBG negative progressive symptomatic metastatic paraganglioma: response and outcome with 177Lu-DOTATATE peptide receptor radionuclide therapy

  2020cites this paper
• Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

  2017cites this paper
• I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma.

  2016cites this paper
• Neuroendocrine Tumors: Therapy with 131 I-MIBG

  2016cites this paper
• The current place and indications of 131I-metaiodobenzylguanidine therapy in the era of peptide receptor radionuclide therapy: determinants to consider for evolving the best practice and envisioning a personalized approach

  2015cites this paper
• 131I‐MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta‐analysis

  2014cites this paper